Quadratus Lumborum Block After Cesarean Section: Analgesic Efficacy of Different Concentrations of Local Anesthetics
Launched by DANAT AL EMARAT HOSPITAL · Dec 1, 2022
Trial Information
Current as of June 30, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a pain relief technique called the quadratus lumborum block (QLB) after a cesarean section. The QLB involves injecting a local anesthetic, which helps to reduce pain in the abdominal area following surgery. The goal of the trial is to compare two different strengths of the anesthetic bupivacaine to see which one is more effective in managing pain after the procedure. Research has shown that using QLB can help lower pain levels, decrease the need for stronger pain medications, and extend the time before additional pain relief is needed.
To participate in this trial, women who are having an elective cesarean section and are in good health (classified as physical status 1 or 2) may be eligible. They must be at least 37 weeks pregnant and agree to take part in the study. However, women with certain health issues, allergies to the medications, or those who have had previous chronic pain problems may not qualify. Those who do participate can expect to receive either of the two concentrations of bupivacaine, which will help researchers understand the best way to use this pain management technique after surgery.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Participants who are American Society of Anesthesiologists physical status 1 or 2.
- • Participants who have singleton pregnancy at a gestation of at least 37 weeks.
- • Participant who are scheduled for elective caesarean section under spinal anesthesia.
- • Participants who are consented to be enrolled into the study.
- Exclusion Criteria:
- • Patients who have contraindications to spinal or regional anesthesia (Coagulopathy or on anticoagulants).
- • Who have Allergy or sensitivity to study medications.
- • Who have anatomical abnormalities or localized infection.
- • Who have history of chronic pain or on regular opioids use.
- • Who are unable to comprehend or unable to use the verbal rating pain scoring system,
- • Failed spinal anesthesia or conversion to general anesthesia after spinal anesthesia.
About Danat Al Emarat Hospital
Danat Al Emarat Hospital is a leading healthcare institution dedicated to delivering exceptional medical services and advancing clinical research in the United Arab Emirates. With a focus on women's health and comprehensive patient care, the hospital integrates state-of-the-art technology with a team of highly skilled professionals to ensure the highest standards of clinical excellence. As a clinical trial sponsor, Danat Al Emarat Hospital is committed to fostering innovative research initiatives that enhance treatment options and improve patient outcomes, while adhering to rigorous ethical standards and regulatory compliance.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Abu Dhabi, , United Arab Emirates
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials